Cen­trex­ion de­lays IPO; Ex­elix­is makes $40M as Cabome­tyx wins EU nod

→ The non-opi­oid painkiller de­vel­op­er Cen­trex­ion, which is led by for­mer Pfiz­er $PFE chief Jef­frey Kindler, has re­port­ed­ly post­poned its IPO. The Boston-based com­pa­ny, whose pipeline of chili-based anal­gesics is be­ing test­ed for a host of pain in­di­ca­tions in hu­mans and an­i­mals, had filed to raise $75 mil­lion by of­fer­ing 5 mil­lion shares at a price range of $14 to $16.

→ Ex­elix­is $EX­EL is set to gain $40 mil­lion from part­ner Ipsen af­ter their can­cer drug Cabome­tyx se­cured Eu­ro­pean ap­proval as a sec­ond-line treat­ment for he­pa­to­cel­lu­lar car­ci­no­ma (HCC) on Thurs­day. The drug is al­ready ap­proved by the FDA for re­nal cell car­ci­no­ma, and the US agency is ex­pect­ed to make a de­ci­sion on its ap­prov­abil­i­ty as a HCC treat­ment by Jan­u­ary 2019.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.